...
首页> 外文期刊>American Journal of Cancer Research >Diagnostic, prognostic and predictive value of MicroRNA-21 in breast cancer patients, their daughters and healthy individuals
【24h】

Diagnostic, prognostic and predictive value of MicroRNA-21 in breast cancer patients, their daughters and healthy individuals

机译:MicroRNA-21在乳腺癌患者,其女儿和健康个体中的诊断,预后和预测价值

获取原文
   

获取外文期刊封面封底 >>

       

摘要

MicroRNA-21 (miR-21) located on 17q23.1 expressed in breast cancer has anti-apoptotic ability and causes tumor cell growth. It is also involved in functions such as signal transduction pathways effecting normal cell growth and differentiation. The primary objective of the study was to identify presence of miR-21 in the serum levels of stage III invasive ductal carcinoma patients and compare its expression with age matched healthy individuals and daughters of index cases. The secondary objective was to evaluate the significance of serum miR-21 gene expression with histologically proven estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) proteins. A total of 132 subjects were recruited: 50 (cases) of stage III invasive ductal carcinoma patients who had not undergone any chemotherapy or surgery were randomly picked with exclusion of females with other types of breast carcinoma. Age-matched, 50 healthy individuals (control A) were selected by purposive sampling after confirmation of no palpable lump/s in their breasts together with 32 daughters of index cases (control B). Serum tests were run on Real Time quantitative Reverse Transcription PCR, threshold cycle was determined and fold change calculated.Normality of continuous variables was assessed by Shapiro-Wilk’s test, groups compared by student t-test, Mann-Whitney test and Fisher exact test, P-value ≤ 0.05 was considered significant. We observed that miR-21 was significantly higher in cases as compared to control A and B (P = 0.001) however control B showed significant gene expression as compared to control A (P = 0.001). The cases were also divided as positive or negative for ER, PR and HER2. High expression of miR-21 in females with stage III invasive ductal carcinoma had been calculated as compared to its age matched healthy subjects. It was observed that triple negative cases showed a greater expression of gene as compared to other groups (P = 0.001). Expression of miR-21 in daughters of the cases was significantly higher as compared to healthy controls but lesser than females with invasive intraductal carcinoma. This result strengthens the concept of inheritability of disease with prediction of miR-21 as a potentially strong diagnostic and prognostic biomarker of breast cancer.
机译:位于乳腺癌中的17q23.1上的MicroRNA-21(miR-21)具有抗凋亡能力,并导致肿瘤细胞生长。它还参与功能,例如影响正常细胞生长和分化的信号转导途径。这项研究的主要目的是鉴定IIIR期浸润性导管癌患者血清中miR-21的存在,并将其与年龄相匹配的健康个体和索引病例的女儿进行比较。第二个目的是评估组织学证明的雌激素受体(ER),孕激素受体(PR)和人表皮生长因子受体2(HER2)蛋白对血清miR-21基因表达的意义。总共招募了132名受试者:随机挑选50例(未进行过任何化学疗法或手术的)III期浸润性导管癌患者,排除患有其他类型乳腺癌的女性。年龄匹配的50名健康个体(对照组A)在确认其乳房中无明显肿块和32例分娩指数的女儿后通过有针对性的抽样(对照组B)进行选择。血清检测采用实时定量逆转录PCR进行,确定阈值循环并计算倍数变化。连续变量的正态性通过Shapiro-Wilk's评估,各组通过学生t检验,Mann-Whitney检验和Fisher精确检验进行比较, P值≤0.05被认为是显着的。我们观察到,与对照组A和B相比,miR-21明显更高(P = 0.001),但是与对照组A相比,对照组B表现出显着的基因表达(P = 0.001)。病例也分为ER,PR和HER2阳性或阴性。与年龄匹配的健康受试者相比,已计算出miR-21在III期浸润性导管癌女性中的高表达。观察到,与其他组相比,三阴性病例显示出更高的基因表达(P = 0.001)。与健康对照组相比,该病例的女儿中miR-21的表达明显较高,但低于浸润性导管内癌的女性。该结果加强了疾病可遗传性的概念,并预测了miR-21作为乳腺癌的潜在强诊断和预后生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号